It takes somewhere between 10 and 15 years—and possibly up to 25—after quitting tobacco for former heavy smokers’ CVD risk to revert to pre-smoking levels, according to a study published August 20 in JAMA.
Istaroxime, a dual action, luso-inotropic agent that’s still in clinical development, was granted fast-track designation by the FDA this month as a possible treatment for HFrEF.
An August 19 science advisory from the AHA states that a 4-gram dose of prescription omega-3 fatty acid medication can greatly reduce people’s triglyceride levels, but patients likely won’t see the same results if they turn to popular—yet unproven—fish oil therapies.
A single dose of the lipid-lowerer simvastatin, delivered to an organ donor pre-heart transplant, could decrease postoperative troponin levels in transplant recipients and protect the donor heart against perioperative myocardial ischemic damage.
A genetic predisposition for insomnia was linked to greater odds of heart disease and stroke—but not atrial fibrillation—in a study of more than a million people with or without CVD.
Fifteen states have now reported more than 120 cumulative cases of vaping-related lung disease or injury, according to the results of a CNN survey of state health departments.
A study published in Radiology August 20 suggests the harm of vaping tobacco products isn’t limited to nicotine itself, with users showing evidence of blood vessel damage even after smoking nicotine-free e-cigs.
The FDA on August 16 granted breakthrough designation to CVRx Inc.’s Barostim Neo System, a device meant to improve heart failure symptoms in patients unsuited for other therapies like CRT.
A machine learning algorithm dubbed “MI3” can reportedly predict a person’s risk of heart attack with more nuance than existing algorithms, prompting its developers to claim it as “one of the first effective demonstrations” of how AI can be used to inform treatment decisions in the cardiology unit.
